

# Michael A Nauck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5147965/publications.pdf>

Version: 2024-02-01

301  
papers

46,910  
citations

3159

92  
h-index

1799

211  
g-index

339  
all docs

339  
docs citations

339  
times ranked

23750  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 311-322.	27.0	5,070
2	The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. <i>Lancet, The</i> , 2006, 368, 1696-1705.	13.7	3,287
3	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	8.6	3,077
4	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015, 38, 140-149.	8.6	2,326
5	Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.. <i>Journal of Clinical Investigation</i> , 1993, 91, 301-307.	8.2	1,401
6	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 1519-1529.	13.7	1,179
7	Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1993, 36, 741-744.	6.3	1,033
8	Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 84-90.	8.6	991
9	Glucagon-like peptide 1 (GLP-1). <i>Molecular Metabolism</i> , 2019, 30, 72-130.	6.5	850
10	Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 63, 492-498.	3.6	752
11	Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects. <i>Diabetes</i> , 1995, 44, 1126-1131.	0.6	721
12	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 11-30.	9.6	653
13	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 194-205.	4.4	601
14	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	6.3	598
15	Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. <i>Diabetes</i> , 1995, 44, 1126-1131.	0.6	559
16	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. <i>Lancet, The</i> , 2010, 375, 1447-1456.	13.7	534
17	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. <i>Lancet, The</i> , 2018, 392, 2180-2193.	13.7	528
18	GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. <i>Molecular Metabolism</i> , 2021, 46, 101102.	6.5	518

#	ARTICLE	IF	CITATIONS
19	Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1239-1246.	3.6	515
20	Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. <i>Diabetes Care</i> , 2011, 34, 2015-2022.	8.6	479
21	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. <i>Lancet</i> , 2013, 381, 117-124.	13.7	466
22	Incretin hormones: Their role in health and disease. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 5-21.	4.4	451
23	Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 273, E981-E988.	3.5	423
24	Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 327-332.	3.6	422
25	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia</i> , 2007, 50, 259-267.	6.3	422
26	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. <i>Circulation</i> , 2017, 136, 849-870.	1.6	415
27	Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. <i>Diabetologia</i> , 2011, 54, 10-18.	6.3	402
28	Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 912-917.	3.6	389
29	Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 203-216.	4.4	322
30	Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 912-917.	3.6	318
31	Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2719-2725.	3.6	315
32	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. <i>Lancet</i> , 2019, 394, 39-50.	13.7	315
33	Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7-36) amide in type I diabetic patients. <i>Diabetes Care</i> , 1996, 19, 580-586.	8.6	310
34	The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 525-536.	11.4	310
35	Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance. <i>Diabetes</i> , 2008, 57, 678-687.	0.6	307
36	Once-weekly abiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 289-297.	11.4	293

#	ARTICLE	IF	CITATIONS
37	Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans. <i>Diabetes</i> , 2011, 60, 1561-1565.	0.6	291
38	Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. <i>Diabetologia</i> , 1996, 39, 1546-1553.	6.3	286
39	Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1335.	4.3	279
40	Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, 654-662.	0.6	277
41	Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5991-5997.	3.6	274
42	Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. <i>Diabetologia</i> , 2003, 46, 798-801.	6.3	270
43	Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications. <i>American Journal of Medicine</i> , 2011, 124, S3-S18.	1.5	255
44	Glucagon-like peptide 1 (GLP-1) in biology and pathology. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 91-117.	4.0	250
45	Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 1163-1172.	4.4	247
46	Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. <i>Diabetologia</i> , 2006, 49, 452-458.	6.3	244
47	Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). <i>Diabetes Care</i> , 2014, 37, 2149-2158.	8.6	236
48	Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans. <i>Gastroenterology</i> , 2006, 130, 44-54.	1.3	218
49	Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. <i>Diabetologia</i> , 1995, 38, 720-725.	6.3	212
50	Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2763-2773.	8.6	211
51	Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. <i>Regulatory Peptides</i> , 2008, 151, 123-129.	1.9	208
52	Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes. <i>Diabetes</i> , 2001, 50, 2497-2504.	0.6	206
53	Gastric Inhibitory Polypeptide: the neglected incretin revisited. <i>Regulatory Peptides</i> , 2002, 107, 1-13.	1.9	197
54	Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 336-347.	4.4	194

#	ARTICLE	IF	CITATIONS
55	Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired $\beta^2$ -Cell Function?. <i>Diabetes</i> , 2010, 59, 1117-1125.	0.6	189
56	A Critical Analysis of the Clinical Use of Incretin-Based Therapies. <i>Diabetes Care</i> , 2013, 36, 2126-2132.	8.6	189
57	Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. <i>International Journal of Clinical Practice</i> , 2009, 63, 46-55.	1.7	187
58	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , 2013, 166, 823-830.e5.	2.7	182
59	Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes. <i>Diabetes</i> , 2004, 53, S190-S196.	0.6	177
60	Glucagon-like Peptide 1 (7-36 hide) Secretion in Response to Luminal Sucrose from the Upper and Lower Gut: A Study Using $\alpha$ -Glucosidase Inhibition (Acarbose). <i>Scandinavian Journal of Gastroenterology</i> , 1995, 30, 892-896.	1.5	176
61	Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intra-gastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1916-1923.	3.6	172
62	Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. <i>Regulatory Peptides</i> , 2005, 128, 135-148.	1.9	160
63	Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study. <i>Diabetes Care</i> , 2010, 33, 1509-1515.	8.6	160
64	MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. <i>European Journal of Endocrinology</i> , 2019, 181, R211-R234.	3.7	156
65	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2438-2444.	8.6	152
66	A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 231-241.	8.6	149
67	Incretin-Based Therapies. <i>Diabetes Care</i> , 2009, 32, S223-S231.	8.6	143
68	GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes. <i>Diabetes</i> , 2011, 60, 1270-1276.	0.6	141
69	The evolving story of incretins (<sc>GIP</sc> and <sc>GLP</sc>â€1) in metabolic and cardiovascular disease: A pathophysiological update. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 5-29.	4.4	139
70	Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1997, 105, 187-195.	1.2	133
71	Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006, 114, 417-423.	1.2	128
72	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1501-1509.	8.6	126

#	ARTICLE	IF	CITATIONS
73	Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 938-946.	4.4	126
74	Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1695-1702.	3.6	125
75	Unraveling the Science of Incretin Biology. <i>American Journal of Medicine</i> , 2009, 122, S3-S10.	1.5	123
76	A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 216-227.	4.4	123
77	Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 525-544.	11.4	121
78	Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia. <i>Diabetes</i> , 2014, 63, 785-790.	0.6	120
79	Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to $\alpha$ -glucosidase inhibition (acarbose) in Type 2 diabetic patients. <i>Diabetes</i> , 1998, 47, 485-491.		119
80	Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E621-E625.	3.5	117
81	Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. <i>Diabetes Care</i> , 1998, 21, 1925-1931.	8.6	116
82	Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. <i>European Journal of Pharmacology</i> , 2002, 440, 269-279.	3.5	115
83	Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects. <i>Diabetes</i> , 2005, 54, 2212-2218.	0.6	113
84	Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 849-858.	4.4	108
85	Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study. <i>Diabetes Care</i> , 2009, 32, 1237-1243.	8.6	107
86	Do GLP-1-Based Therapies Increase Cancer Risk?. <i>Diabetes Care</i> , 2013, 36, S245-S252.	8.6	106
87	Insulinotropic Properties of Synthetic Human Gastric Inhibitory Polypeptide in Man: Interactions with Glucose, Phenylalanine, and Cholecystokinin-8. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 69, 654-662.	3.6	105
88	Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. <i>Acta Diabetologica</i> , 1995, 32, 13-16.	2.5	105
89	Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. <i>Regulatory Peptides</i> , 2004, 122, 209-217.	1.9	105
90	The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4165-4171.	3.6	105

#	ARTICLE	IF	CITATIONS
91	The pathogenesis of NIDDM involves a defective expression of the GIP receptor. <i>Diabetologia</i> , 1997, 40, 984-986.	6.3	104
92	Is glucagon-like peptide 1 an incretin hormone?. <i>Diabetologia</i> , 1999, 42, 373-379.	6.3	100
93	Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. <i>British Heart Journal</i> , 2004, 90, 9-12.	2.1	96
94	Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1111-1120.	4.4	93
95	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, 1546-1552.	8.6	92
96	The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E1118-E1123.	3.5	90
97	Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without) Tj ETQq1 1 0.784314 rgBT / <i>Overlook and Metabolism</i> , 2015, 17, 1056-1064.	4.4	89
98	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.	1.6	88
99	Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. <i>Critical Care Medicine</i> , 2004, 32, 848-851.	0.9	87
100	Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52-week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. <i>Diabetologia</i> , 2016, 59, 266-274.	6.3	85
101	Risk of pancreatitis in patients treated with incretin-based therapies. <i>Diabetologia</i> , 2014, 57, 1320-1324.	6.3	84
102	The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. <i>Diabetologia</i> , 2005, 48, 608-611.	6.3	83
103	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , 2018, 138, 2884-2894.	1.6	82
104	Incretins and the development of type 2 diabetes. <i>Current Diabetes Reports</i> , 2006, 6, 194-201.	4.2	81
105	Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and Intravenous Glucose. <i>Diabetes</i> , 2014, 63, 663-674.	0.6	80
106	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. <i>Circulation</i> , 2018, 137, 2179-2183.	1.6	80
107	Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. <i>Acta Diabetologica</i> , 1998, 35, 117-129.	2.5	75
108	Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. <i>Diabetologia</i> , 2007, 50, 806-813.	6.3	75

#	ARTICLE	IF	CITATIONS
109	Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 699-704.	4.4	75
110	Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, S220-S224.	0.6	73
111	Plasma Glucose at Hospital Admission and Previous Metabolic Control Determine Myocardial Infarct Size and Survival in Patients With and Without Type 2 Diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). <i>Diabetes Care</i> , 2005, 28, 2551-2553.	8.6	73
112	GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial. <i>Diabetologia</i> , 2015, 58, 1759-1768.	6.3	73
113	Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. <i>Diabetologia</i> , 2005, 48, 1872-1881.	6.3	72
114	Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 499-508.	4.4	71
115	Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. <i>Peptides</i> , 1998, 19, 1049-1053.	2.4	69
116	Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). <i>European Heart Journal</i> , 2000, 21, 220-229.	2.2	69
117	Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E849-E856.	3.5	65
118	Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2017, 40, 966-972.	8.6	63
119	Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance. <i>Diabetes</i> , 2001, 50, 776-784.	0.6	62
120	Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes. <i>Hormone and Metabolic Research</i> , 2004, 36, 852-858.	1.5	61
121	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. <i>Peptides</i> , 2020, 125, 170183.	2.4	61
122	Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as $\alpha$ -celsoglycemicâ€•Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 945-954.	3.6	60
123	Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1986-1993.	8.6	58
124	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. <i>Diabetes Care</i> , 2014, 37, 2647-2659.	8.6	58
125	Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 238-248.	7.1	55
126	$\alpha$ -Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. <i>Diabetic Medicine</i> , 2005, 22, 470-476.	2.3	54



#	ARTICLE	IF	CITATIONS
127	LEADER 3â€”Lipase and Amylase Activity in Subjects With Type 2 Diabetes. <i>Pancreas</i> , 2014, 43, 1223-1231.	1.1	54
128	Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 2303-2312.	8.6	54
129	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the <sc>DEVOTE</sc>, <sc>LEADER</sc> and <sc>SUSTAIN</sc>â€™ cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1537-1547.	4.4	54
130	Glucagon-Like Peptide 1 and its Potential in the Treatment of Non-Insulin-Dependent Diabetes Mellitus. <i>Hormone and Metabolic Research</i> , 1997, 29, 411-416.	1.5	53
131	The novel dual glucoseâ€”dependent insulinotropic polypeptide and glucagonâ€”like peptideâ€”1 (<sc>GLP</sc>â€”1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <sc>longâ€”acting GLP</sc>â€”1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1886-1891.	4.4	53
132	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1128-1141.	2.8	53
133	Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide. <i>BioDrugs</i> , 2003, 17, 93-102.	4.6	52
134	Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004, 18, 587-606.	4.7	52
135	Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2018, 41, 1663-1671.	8.6	51
136	Lack of Effect of Synthetic Human Gastric Inhibitory Polypeptide and Glucagon-Like Peptide 1 [7-36 Amide] Infused at Near-Physiological Concentrations on Pentagastrin-Stimulated Gastric Acid Secretion in Normal Human Subjects. <i>Digestion</i> , 1992, 52, 214-221.	2.3	49
137	Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. <i>Acta Diabetologica</i> , 1993, 30, 39-45.	2.5	47
138	Hypoglycemia due to Paraneoplastic Secretion of Insulin-Like Growth Factor-I in a Patient with Metastasizing Large-Cell Carcinoma of the Lung. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1600-1605.	3.6	47
139	Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11Î²-Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids. <i>Diabetes</i> , 2012, 61, 292-300.	0.6	47
140	Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. <i>European Journal of Endocrinology</i> , 2008, 158, 773-784.	3.7	45
141	Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2 diabetic patients. , 1998, 15, 937-945.		43
142	Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1579-1585.	3.4	43
143	Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 213-222.	4.4	43
144	Unraveling the Science of Incretin Biology. <i>European Journal of Internal Medicine</i> , 2009, 20, S303-S308.	2.2	43

#	ARTICLE	IF	CITATIONS
145	Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines—a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems. <i>Diabetic Medicine</i> , 2014, 31, 1078-1085.	2.3	43
146	Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. <i>Diabetes</i> , 2016, 65, 2440-2447.	0.6	43
147	GIP as a Potential Therapeutic Agent?. <i>Hormone and Metabolic Research</i> , 2004, 36, 859-866.	1.5	42
148	Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. <i>Frontiers in Endocrinology</i> , 2021, 12, 645566.	3.5	42
149	Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2048-2053.	8.6	41
150	Incretins and their analogues as new antidiabetic drugs. <i>Drug News and Perspectives</i> , 2003, 16, 413.	1.5	40
151	Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. <i>Regulatory Peptides</i> , 2004, 118, 89-97.	1.9	39
152	Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 606-607.	2.8	39
153	Incretin-based therapies: where will we be 50 years from now?. <i>Diabetologia</i> , 2015, 58, 1745-1750.	6.3	39
154	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events. <i>JAMA Cardiology</i> , 2019, 4, 1214.	6.1	39
155	GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family. <i>Diabetes</i> , 2019, 68, 897-900.	0.6	39
156	Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 2359-2366.	6.3	39
157	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S73-S92.	1.2	38
158	Long COVID—metabolic risk factors and novel therapeutic management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 379-380.	9.6	38
159	Critical evaluation of the “heated and” technique™ for obtaining “arterialized” venous blood: incomplete arterialization and alterations in glucagon responses. <i>Clinical Physiology</i> , 1992, 12, 537-552.	0.7	37
160	Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?. <i>Diabetologia</i> , 2013, 56, 1878-1883.	6.3	36
161	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> , 2019, 42, 1912-1920.	8.6	35
162	Diagnostic Accuracy of an “Amended” Insulin-Glucose Ratio for the Biochemical Diagnosis of Insulinomas. <i>Annals of Internal Medicine</i> , 2012, 157, 767.	3.9	34

#	ARTICLE	IF	CITATIONS
163	Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1995, 268, E949-E955.	3.5	33
164	Comparison of Pancreas-Transplanted Type 1 Diabetic Patients with Portal-Venous Versus Systemic-Venous Graft Drainage: Impact on Glucose Regulatory Hormones and the Growth Hormone/Insulin-Like Growth Factor-I Axis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1758-1766.	3.6	32
165	Confronting the Type 2 Diabetes Epidemic: the Emerging Role of Incretin-Based Therapies. <i>American Journal of Medicine</i> , 2010, 123, S2-S10.	1.5	32
166	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1-9.	3.6	32
167	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001706.	2.8	31
168	Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards. <i>Diabetes Care</i> , 2020, 43, 2906-2909.	8.6	30
169	Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 200-207.	4.4	28
170	Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients. <i>Diabetologia</i> , 1996, 39, 462-468.	6.3	27
171	Combined Pancreas and Kidney Transplantation in a Lean Type 2 Diabetic Patient. Effects on Insulin Secretion and Sensitivity. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2002, 110, 420-424.	1.2	27
172	Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits. <i>Postgraduate Medicine</i> , 2009, 121, 5-15.	2.0	27
173	Cloning and quantitative determination of the human Ca <sup>2+</sup> /calmodulin-dependent protein kinase II (CaMK II) isoforms in human beta cells. <i>Diabetologia</i> , 2000, 43, 465-473.	6.3	26
174	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. <i>Diabetes Research and Clinical Practice</i> , 2017, 131, 49-60.	2.8	26
175	To be or not to be--an incretin or enterogastrone?. <i>Gut</i> , 2006, 55, 148-150.	12.1	25
176	Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). <i>American Journal of Cardiology</i> , 2018, 121, 1467-1470.	1.6	25
177	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018, 138, 1605-1607.	1.6	25
178	GLP-1 analogues and insulin: sound the wedding bells?. <i>Nature Reviews Endocrinology</i> , 2011, 7, 193-195.	9.6	24
179	Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2007, 10, 070509203705001-???	4.4	23
180	Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , 2018, 9, 2383-2392.	2.5	23

#	ARTICLE	IF	CITATIONS
181	SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 424-442.	7.1	23
182	Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 465-468.	2.0	22
183	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1745-1751.	4.4	22
184	Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998, 106, 103-107.	1.2	21
185	Preserved GLP-1 Effects in a Diabetic Patient with Cushing's Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, 146-150.	1.2	21
186	Defects in $\beta$ -Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals. <i>Diabetes Care</i> , 2017, 40, 1314-1322.	8.6	21
187	Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 525-532.	4.4	21
188	Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2137-2145.	8.6	21
189	Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 410.	4.7	21
190	Role of Endogenously Released Cholecystokinin in Determining Postprandial Insulin Levels in Man: Effects of Loxiglumide, a Specific Cholecystokinin Receptor Antagonist. <i>Digestion</i> , 1992, 53, 189-199.	2.3	20
191	Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 868-877.	4.4	20
192	Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. <i>Diabetes Care</i> , 2017, 40, 647-654.	8.6	20
193	Influence of an Antidiabetic Treatment with Sulfonylurea Drugs on Long-Term Survival after Acute Myocardial Infarction in Patients with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2003, 111, 344-350.	1.2	19
194	Comment to: Patti ME, McMahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. <i>Diabetologia</i> 48:2236-2240. <i>Diabetologia</i> , 2006, 49, 607-608.	6.3	19
195	The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. <i>Diabetologia</i> , 2007, 50, 2413-2416.	6.3	19
196	Incretin-based therapies in 2021 – Current status and perspectives for the future. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154843.	3.4	19
197	The reduction in hepatic insulin clearance after oral glucose is not mediated by Gastric inhibitory polypeptide (GIP). <i>Regulatory Peptides</i> , 2003, 113, 95-100.	1.9	18
198	Postoperative oral glucose tolerance and stimulated insulin secretion: a predictor of endocrine graft function more than 10 years after pancreas-kidney transplantation. <i>Transplantation</i> , 2003, 76, 1427-1431.	1.0	18

#	ARTICLE	IF	CITATIONS
199	Glucagon-like peptide-1 in type 2 diabetes: the $\beta$ -cell and beyond. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 2-13.	4.4	18
200	<sc>LEADER</sc> 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the <sc>L</sc>iraglutide <sc>E</sc>ffect and <sc>A</sc>ction in <sc>D</sc>iabetes: <sc>E</sc>valuation of cardiovascular outcome <sc>R</sc>esults (<sc>LEADER</sc>) trial: preliminary observations. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 477-486.	4.4	18
201	Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study. <i>Critical Care</i> , 2015, 19, 20.	5.8	18
202	Prolonged Maximal Stimulation of Insulin Secretion in Healthy Subjects Does Not Provoke Preferential Release of Proinsulin. <i>Pancreas</i> , 1991, 6, 645-652.	1.1	17
203	Comparison of hyperinsulinaemic clamp experiments using venous, $\tilde{\text{arterialized}}$ venous or capillary euglycaemia. <i>Clinical Physiology</i> , 1996, 16, 589-602.	0.7	17
204	Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic $\beta$ -cell area. <i>European Journal of Endocrinology</i> , 2010, 163, 551-558.	3.7	17
205	Feedback suppression of meal-induced glucagon-like peptide-1 (<sc>GLP</sc>-1) secretion mediated through elevations in intact <sc>GLP</sc>-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1100-1109.	4.4	17
206	GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 963-964.	11.4	17
207	Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardiovascular outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1327-1328.	4.4	17
208	Absence of a Memory Effect for the Insulinotropic Action of Glucagon-like Peptide 1 (GLP-1) in Healthy Volunteers. <i>Hormone and Metabolic Research</i> , 2003, 35, 551-556.	1.5	16
209	On the Effects of Glucagon-Like Peptide-1 on Blood Glucose Regulation in Normal and Diabetic Subjects. <i>Annals of the New York Academy of Sciences</i> , 1996, 805, 729-736.	3.8	16
210	Absence of severe hyperinsulinemia after pancreas/kidney transplantation with peripheral venous drainage. <i>Transplantation Proceedings</i> , 1997, 29, 645-646.	0.6	15
211	A hyperinsulinaemic, sequentially eu- and hypoglycaemic clamp test to characterize autonomous insulin secretion in patients with insulinoma. <i>European Journal of Clinical Investigation</i> , 2003, 27, 109-115.	3.4	15
212	Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6201-6206.	3.6	15
213	Importance of localization of insulinomas: a systematic analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2019, 26, 383-392.	2.6	15
214	Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , 2022, 39, e14669.	2.3	15
215	Individualised incretin-based treatment for type 2 diabetes. <i>Lancet, The</i> , 2010, 376, 393-394.	13.7	14
216	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019, 18, 116.	6.8	14

#	ARTICLE	IF	CITATIONS
217	A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers. <i>Acta Diabetologica</i> , 1997, 34, 230-234.	2.5	13
218	Response to comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia</i> 50:259â€“267. <i>Diabetologia</i> , 2007, 50, 1563-1564.	6.3	13
219	A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment. <i>Diabetologia</i> , 2014, 57, 868-877.	6.3	13
220	Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretinâ€based therapies. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1253-1262.	4.4	13
221	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E284-E291.	3.5	13
222	GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 262-264.	11.4	13
223	Islet Amyloid in Patients With Diabetes Due to Exocrine Pancreatic Disorders, Type 2 Diabetes, and Nondiabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2595-2605.	3.6	13
224	Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1330-1339.	3.4	12
225	The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. <i>Metabolism: Clinical and Experimental</i> , 2020, 103, 154031.	3.4	12
226	Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII). <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 360-370.	2.2	12
227	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2193-2198.	4.4	11
228	Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. <i>Diabetologia</i> , 1995, 38, 720-725.	6.3	11
229	A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome. <i>Acta Diabetologica</i> , 2003, 40, 163-172.	2.5	10
230	Comparative evaluation of incretinâ€based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failureâ€. <i>Journal of Diabetes Investigation</i> , 2010, 1, 24-36.	2.4	10
231	Fasting C-peptide and Related Parameters Characterizing Insulin Secretory Capacity for Correctly Classifying Diabetes Type and for Predicting Insulin Requirement in Patients with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2016, 124, 148-156.	1.2	10
232	Improvement in glycated haemoglobin evaluated by baseline body mass index: a metaâ€analysis of the liraglutide phase <sc>III</sc> clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 707-710.	4.4	10
233	Sitagliptin plus basal insulin: simplifying in-hospital diabetes treatment?. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 83-85.	11.4	10
234	Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on mealâ€related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 599-611.	4.4	10

#	ARTICLE	IF	CITATIONS
235	Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 479-488.	8.6	10
236	The design of the liraglutide clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 4-12.	4.4	9
237	Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 721-724.	4.4	9
238	Metabolomic linkage reveals functional interaction between glucose-dependent insulinotropic polypeptide and ghrelin in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 301, E608-E617.	3.5	8
239	Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance. <i>Diabetes Care</i> , 2015, 38, e7-e8.	8.6	8
240	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2450-2458.	4.4	8
241	Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1262-1272.	2.2	8
242	Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2344-2353.	4.4	8
243	Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls. <i>World Journal of Gastroenterology</i> , 2006, 12, 1874.	3.3	8
244	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	6.8	8
245	Basal and nutrient-stimulated pancreatic and gastrointestinal hormone concentrations in type-1-diabetic patients after successful combined pancreas and kidney transplantation. <i>The Clinical Investigator</i> , 1992, 70, 40-48.	0.6	7
246	Effect of portal glucose sensing on incretin hormone secretion in a canine model. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E244-E249.	3.5	7
247	Measurement of Gastric Emptying Using a 13C-octanoic Acid Breath Test with Wagner-Nelson Analysis and Scintigraphy in Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, 751-757.	1.2	7
248	Six Methods for the Determination of C-Peptide Evaluated. <i>Clinical Chemistry and Laboratory Medicine</i> , 1999, 37, 745-51.	2.3	6
249	Impact of Exogenous Hyperglucagonemia on Postprandial Concentrations of Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4061-4065.	3.6	6
250	Pancreatitis and incretin-based drugs: clarity or confusion?. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 92-93.	11.4	6
251	Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy – A Retrospective Observational Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 663-671.	1.2	6
252	Self-Monitoring of Blood Glucose in Diabetes Mellitus. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2009, 106, 587-94.	0.9	6

#	ARTICLE	IF	CITATIONS
253	Genetic Determinants Predicting Efficacy of Glucose-Lowering Drugs?: A long way to go .... Diabetes Care, 2010, 33, 2123-2125.	8.6	5
254	Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. Diabetes and Vascular Disease Research, 2016, 13, 286-298.	2.0	5
255	A case series of verrucae vulgares mimicking hyperkeratosis in individuals with diabetic foot ulcers. Diabetic Medicine, 2017, 34, 1165-1168.	2.3	5
256	Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. International Journal of Clinical Practice, 2018, 72, e13240.	1.7	5
257	The relationship between plasma GIP and GLP-1 levels in individuals with normal and impaired glucose tolerance. Acta Diabetologica, 2020, 57, 583-587.	2.5	5
258	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S80-S112.	1.2	5
259	SA0010 EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	4
260	FP483 EFFECTS OF SEMAGLUTIDE AND LIRAAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	4
261	Pioneering oral peptide therapy for patients with type 2 diabetes. Lancet Diabetes and Endocrinology, 2019, 7, 500-502.	11.4	4
262	Owning a Dog as a Determinant of Physical Activity and Metabolic Control in Patients With Type 1 and Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 379-384.	1.2	4
263	Novel approaches to treating type 2 diabetes. Diabetologia, 2016, 59, 227-228.	6.3	3
264	FP482 EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	3
265	No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects. Peptides, 2020, 125, 170176.	2.4	3
266	Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy. Journal of Diabetes Science and Technology, 2020, 15, 193229682097269.	2.2	3
267	Voices: Insulin and beyond. Cell Metabolism, 2021, 33, 692-699.	16.2	3
268	Another milestone in the evolution of GLP-1-based diabetes therapies. Nature Medicine, 2021, 27, 952-953.	30.7	3
269	DOES GLUCAGON STIMULATION PREDICT ORAL GLUCOSE TOLERANCE IN PATIENTS AFTER SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION?1. Transplantation, 2000, 70, 545-547.	1.0	3
270	Understanding the restrictions in the prescription and use of potentially beneficial diabetes medications associated with low socio-economic status. Lancet Regional Health - Europe, The, 2022, 14, 100318.	5.6	3



#	ARTICLE	IF	CITATIONS
271	Insulin clearance and incretin hormones following oral and $\alpha$ -isoglycemic intravenous glucose in type 2 diabetes patients under different antidiabetic treatments. <i>Scientific Reports</i> , 2022, 12, 2510.	3.3	3
272	Prediction of glucose tolerance with glucagon stimulation in pancreas transplanted patients. <i>Transplantation Proceedings</i> , 1997, 29, 3122-3123.	0.6	2
273	Modified hyperinsulinaemic, eu- and hypoglycaemic clamp technique using lispro-insulin for insulinoma diagnostic. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2001, 109, 397-401.	1.2	2
274	Orlistat Augments Postprandial Increases in Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Damci et al.. <i>Diabetes Care</i> , 2004, 27, 2770-2770.	8.6	2
275	Glycaemic Rises after Waking Up in Response to an Alarm Clock in Type 1-diabetic Patients Analysed with Continuous Glucose Monitoring (GlucoDay <sup>®</sup> S). <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011, 119, 56-58.	1.2	2
276	In vivo effect of glucose-dependent insulinotropic peptide (GIP) on the gene expression of calcitonin peptides in human subcutaneous adipose tissue. <i>Regulatory Peptides</i> , 2012, 179, 29-32.	1.9	2
277	A1C Improvement with Liraglutide Evaluated by Baseline BMI. <i>Canadian Journal of Diabetes</i> , 2013, 37, S35-S36.	0.8	2
278	Incretin mimetics and insulin $\alpha$ closing the gap to normoglycaemia. <i>Nature Reviews Endocrinology</i> , 2016, 12, 689-690.	9.6	2
279	Break point instead of ACE: acarbose, post-load glycaemic excursions, and cardiovascular events. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 843-845.	11.4	2
280	Reply to: Autonomic dyshomeostasis in patients with diabetes mellitus during COVID-19. <i>Nature Reviews Endocrinology</i> , 2021, 17, 189-190.	9.6	2
281	58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist. <i>Diabetes</i> , 2019, 68, 58-OR.	0.6	2
282	Liraglutide Effects in Insulin-Treated Patients in LEADER. <i>Diabetes</i> , 2018, 67, 438-P.	0.6	2
283	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. <i>Lancet</i> , 2002, 360, 257.	13.7	1
284	Preface. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, vii.	4.7	1
285	Diagnostic Accuracy of an $\alpha$ -Amended $\alpha$ -Insulin $\alpha$ Glucose Ratio for the Biochemical Diagnosis of Insulinomas. <i>Annals of Internal Medicine</i> , 2013, 158, 501.	3.9	1
286	The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1. <i>Diabetologia</i> , 2016, 59, 966-969.	6.3	1
287	Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial. <i>Canadian Journal of Diabetes</i> , 2017, 41, S5.	0.8	1
288	Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> 2019;42:1912-1920. <i>Diabetes Care</i> , 2020, 43, e30-e31.	8.6	1

#	ARTICLE	IF	CITATIONS
289	SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?. <i>Endocrinology</i> , 2020, 161, .	2.8	1
290	993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, 993-P.	0.6	1
291	Effects of single and combined infusions of human biosynthetic proinsulin and insulin on glucose metabolism and on plasma hormone concentrations in euglycaemic clamp experiments. <i>Hormone and Metabolic Research Supplement Series</i> , 1988, 18, 60-7.	0.2	1
292	Has a single blood glucose estimation on admission to hospital any prognostic value for acute pancreatitis?. <i>Gastroenterology</i> , 2000, 118, A1143.	1.3	0
293	For Insulinomas, No Place to Hide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4125-4126.	3.6	0
294	Basal rate tests (24-hour fasts) performed in type 1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: <scp>A</scp> randomized controlled prospective trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 783-790.	4.4	0
295	Risk of hypoglycaemia associated with professional, recreational, and traffic-related activities in patients with type 2 diabetes: a cross-sectional study by questionnaire. <i>Acta Diabetologica</i> , 2020, 57, 965-972.	2.5	0
296	Incretin Hormone Release Does Not Involve Hepatic Portal Vein Glucose Sensors. <i>Diabetes</i> , 2018, 67, 1961-P.	0.6	0
297	55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4. <i>Diabetes</i> , 2019, 68, .	0.6	0
298	Acute effects of linagliptin on intact and total glucagon-like peptide 1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 806-815.	4.4	0
299	Comment: Type 1 diabetes and oral health: Findings from the Epidemiology of Diabetes Interventions and Complications (EDIC) study. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108146.	2.3	0
300	Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective. <i>Diabetes and Metabolism Journal</i> , 2022, , .	4.7	0
301	Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2). <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0